Clinical Trial Update: The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study [Phase 2]

View source ↗

Summary

Phase 2 open-label cohort study evaluating the safety and efficacy of MRG003, with or without Putrelimab, in recurrent or metastatic salivary gland carcinoma; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Carcinoma

Drugs mentioned

• MRG003
• Putrelimab (Putrelimab)

Snippet

Sponsor: Ji Dongmei | Conditions: Salivary Gland Carcinomas | Phase 2 | Status: RECRUITING